Incyte Co. (NASDAQ:INCY) Shares Acquired by Compagnie Lombard Odier SCmA

Compagnie Lombard Odier SCmA grew its position in Incyte Co. (NASDAQ:INCY) by 15,833.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,120 shares of the biopharmaceutical company’s stock after acquiring an additional 19,000 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Incyte were worth $1,158,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Wells Fargo & Company MN boosted its holdings in shares of Incyte by 61.3% in the fourth quarter. Wells Fargo & Company MN now owns 174,190 shares of the biopharmaceutical company’s stock valued at $12,031,000 after acquiring an additional 66,220 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Incyte by 13.5% during the fourth quarter. JPMorgan Chase & Co. now owns 323,640 shares of the biopharmaceutical company’s stock worth $22,354,000 after purchasing an additional 38,550 shares during the period. Pictet Asset Management Holding SA lifted its holdings in shares of Incyte by 73.4% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,313,873 shares of the biopharmaceutical company’s stock worth $90,749,000 after purchasing an additional 556,218 shares during the period. Commonwealth Equity Services LLC lifted its holdings in shares of Incyte by 2.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 30,527 shares of the biopharmaceutical company’s stock worth $2,109,000 after purchasing an additional 782 shares during the period. Finally, Mercer Global Advisors Inc. ADV lifted its holdings in shares of Incyte by 131.4% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,624 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 4,329 shares during the period. 96.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on INCY shares. Truist Financial increased their price target on Incyte from $72.00 to $73.00 and gave the stock a “hold” rating in a report on Tuesday, May 27th. UBS Group reaffirmed a “neutral” rating and set a $61.00 price target on shares of Incyte in a report on Tuesday, June 3rd. Royal Bank of Canada increased their price target on Incyte from $64.00 to $67.00 and gave the stock a “sector perform” rating in a report on Wednesday, April 30th. Citigroup reaffirmed a “buy” rating on shares of Incyte in a report on Tuesday, June 3rd. Finally, Guggenheim downgraded Incyte from a “buy” rating to a “neutral” rating and set a $92.00 price target for the company. in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $72.53.

Incyte Trading Up 0.5%

NASDAQ:INCY opened at $69.22 on Friday. The stock has a fifty day moving average price of $62.09 and a two-hundred day moving average price of $67.14. The stock has a market capitalization of $13.40 billion, a price-to-earnings ratio of 256.38, a PEG ratio of 0.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. Incyte Co. has a 1 year low of $53.56 and a 1 year high of $83.95.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.15. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $996.17 million. During the same quarter last year, the business posted $0.64 earnings per share. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.